Rare Disease Biotech Offers Access Ahead of Key Milestone
This late-stage biotech is gearing up for Phase 2 trials with an FDA-designated orphan drug. It's already drawing comparisons to recent billion-dollar exits. Backed by a proven biotech incubator, it's now offering early access to its raise.
Shares Stats
| Shares Outstanding | 679,880,000 |
| Shares Float | 678,020,000 |
| Shares Short | 6,880,000 |
| Insider Holdings | 9% |
| Institution Holdings | 86.82% |
About Corteva Inc
Corteva, Inc. operates in the agriculture business. It operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait technologies that enhance resistance to weather, disease, insects, and herbicides used to control weeds, as well as food and nutritional characteristics. This segment also provides digital solutions that assist farmer decision-making with a view to optimize product selection, and maximize yield and profitability. The Crop Protection segment offers products that protect against weeds, insects and other pests, and diseases, as well as enhances crop health above and below ground through nitrogen management and seed-applied technologies. This segment provides herbicides, insecticides, nitrogen stabilizers, and pasture and range management herbicides. It serves agricultural input industry. The company operates in the United States, Canada, Latin America, the Asia Pacific, Europe, the Middle East, and Africa. Corteva, Inc. was incorporated in 2018 and is headquartered in Indianapolis, Indiana.
General
| Name | Corteva Inc |
| Ticker | CTVA |
| Exchange | NYSE |
| Sector | Basic Materials |
| Industry | Agricultural Inputs |
| Currency | USD |
| Country | USA |
| Fiscal Year End | December |
| Full Time Employees | 22,000 |
Highlights
| Analyst Target | 80.57 |
| Market Cap | 43,116,100,000 |
| PE Ratio | 30.89 |
| PEG Ratio | 1.55 |
| EBITDA | 3,569,999,872 |
Financials
| Curr Year EPS Estimate | 3.13 |
| Next Quarter EPS Estimate | -0.37 |
| Profit Margin | 8.16% |
| Operating Margin | 13.86 |
| Return on Assets | 0.04 |
| Return on Equity | 0.06 |
| Revenue | 17.2B |
| Earnings Per Share | 1.96 |
| Revenue Per Share | 25.03 |
| Gross Profit | 7,841,999,872 |
| Quarterly Revenue Growth | 0.06 |
Valuation
| Trailing PE | 31.36 |
| Forward PE | 18.90 |
| Price/Sales (Trailing 12 Mt.) | 2.69 |
| Price/Book (Most Recent Quarter) | 1.78 |
Dividend
Corteva Inc pays out a dividend of $0.70 per share, with a dividend yield of 1.10%.
CTVA's last dividend payment was made to shareholders on September 15, 2025.
They pay out 50.64% of their earnings out as a dividend.
Recent Dividends
| Sep 15, 2025 | $0.18 |
| Jun 16, 2025 | $0.17 |
| Mar 17, 2025 | $0.17 |
| Dec 16, 2024 | $0.17 |
| Sep 17, 2024 | $0.17 |
| Jun 18, 2024 | $0.16 |
| Mar 15, 2024 | $0.16 |
| Dec 15, 2023 | $0.16 |
Trump administration cuts nearly $8B in clean energy projects in blue states
WASHINGTON (AP) — The Trump administration is cancelling $7.6 billion in grants that supported hundreds of clean energy projects in 16 states, all of which voted for Democrat Kamala Harris in last year's presidential election.
Nvidia's Value Reaches $4.6 Trillion, Bitcoin Eyes $120,000: What's Moving Markets Thursday?
On the second day of the U.S. government shutdown, Wall Street remains largely subdued, with indexes showing only slight midday declines after touching fresh record highs at the open.
Biotech With Multiple Orphan Drugs Is Quietly Opening Its Doors - Ad
A promising biotech developing treatments for rare childhood brain diseases is opening a new raise. Its lead drug has fast-track status, orphan designations, is nearing Phase 2 and backed by a Global Integrator.
When Bill Gates Questioned Lyft CEO Risher's Move To Jeff Bezos' 'Tiny, Little Internet Bookstore'—'Stupidest Decision' Ever
David Risher, current CEO of Lyft Inc recently shared a bold career move he made in 1996 that earned him a scathing rebuke from Bill Gates.
FAA Faces Furlough Of 11,000 Employees, Airlines Warn Of Delays Amid Shutdown Threat
11,000 FAA employees face potential furloughs due to government funding lapse. ATC and TSA workers would work without pay.
New Biotech Offering Targets $426B Rare Disease Market - Ad
The rare disease drug space is growing fast-and so is investor interest. With exclusivity, pricing power and major M&A moves, the rare disease space is getting interesting. This company has the science and the experience.
OpenAI's Deal Machine Is in Overdrive—From CoreWeave To UiPath And Walmart
OpenAI has accelerated its partnership engine dramatically and is reshaping the tech, enterprise and retail landscapes at a dizzying pace.
Cathie Wood Dumps $5.2 Million Worth of This AI Stock, Here's What Ark Bought Instead
Ark Invest decided to sell shares of Tempus AI (TEM), despite positive news of FDA clearance for its diagnostic device. They also made other key trades.
Elon's $25 Trillion Confession - Ad
Elon Musk: "Tesla will become a $25 trillion company." That would make Tesla 8x bigger than Apple today. How is that possible? He admits it's all thanks to this one AI breakthrough that will take AI out of our computer screens and manifest a 250x boom here in the real world.
3 Gold Mining Stocks Shine As Prices Hit Records
Gold mining stocks Anglogold Ashanti, Coeur Mining, and New Gold join the top 10% for quality as gold prices hit fresh highs.
Jensen Huang Is A 'Good Friend,' Says Intel CEO Lip-Bu Tan Amid News Of Partnership With Nvidia: Next Era Of Computing Coming?
Intel shares surged more than 20% after CEO Lip-Bu Tan announced a landmark partnership with Nvidia's Jensen Huang to co-develop AI chips, a deal that includes a $5 billion Nvidia investment and positions both companies at the center of the next era of computing.
Why This Crypto Skeptic Had a Change of Heart - Ad
He used to make fun of crypto. Now... he says one $3 crypto could rise to $92 by next year.
Actor Playing Elon Musk In OpenAI Movie Doesn't Want To Meet Tesla CEO: 'Poisoning My Brain By Watching Lots Of Interviews With Him'
An upcoming 2026 film about OpenAI will see an actor play the role of Elon Musk. Here's how the actor is preparing for playing the billionaire.
PepsiCo May See Lower Q3 Gross Margins From Tariff Pressure, 'Stretched' Frito-Lay Pricing
PepsiCo, Inc. (NASDAQ: PEP) shares are trading slightly higher on Friday.
The Tesla Shock Nobody Sees Coming - Ad
While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
Ethereum Co-Founder Vitalik Buterin Responds to Security Concerns Over OpenAI's ChatGPT
Ethereum co-founder Vitalik Buterin has voiced his concerns over potential security risks associated with OpenAI's ChatGPT, which could lead to the leakage of personal user data.
New York City's Wealthiest Neighborhoods Witness 60% Rent Surge Since Pandemic
House rental rates in some of the wealthiest neighborhoods of New York City have surged by over 60% since the COVID-19 pandemic began, putting even high-income earners in a tight spot.
Gold Is Being Reintroduced Into the Monetary System - Ad
While the media focuses on political scandals, inflation and coming up with ridiculous acronyms "TACO"... Smart money is tracking a far bigger shift: a gold revaluation is quietly underway. Garrett Goggin, CFA, says this could trigger 100X moves in select miners - and he's identified four with the biggest upside.
Robert Kiyosaki Blasts Mutual Funds and ETFs as 'For Losers,' Backs Trump's XO for Alternative Investments
Robert Kiyosaki has expressed approval for President Trump's recent executive order, which he believes will democratize access to alternative investments for 401k investors.
Tesla, Warner Bros. Discovery Get Partial Victory In AI Image Lawsuit From 'Blade Runner' Production Company
Tesla may have used images similar to "Blade Runner 2049" during its robotaxi event, according to a lawsuit. Here's an update on the case.
How the Multiplier Effect is Working on This $3 Crypto - Ad
It's called the multiplier effect in crypto. In short, because of a lack of supply, small inflows of cash can create major moves in the overall value of the crypto. And it's particularly strong in one $3 crypto. Crypto analysts are suggesting it could rise to as high as $100 by next year.
Meta Unveils $499 Oakley Vanguard And $799 Ray-Ban Display Smart Glasses At Connect 2025: Gene Munster Says 'Best Bang For The Buck'
Meta unveiled its $499 Oakley Vanguard and $799 Ray-Ban Display smart glasses at Connect 2025, with Gene Munster calling the Ray-Ban model the "best bang for the buck" as competition with Apple heats up.
Warner Bros, Oracle, And Micron Technology Are Among The Top 10 Large-Cap Gainers Last Week (Sep. 8 - Sep. 12): Are The Others In Your Portfolio?
Deal buzz, analyst upgrades, and AI momentum drove top weekly gainers—led by Warner Bros., Oracle, and Micron—across large-cap tech and media.
The "Mar-A-Lago Accord" Is Now Underway - Ad
The global order is in chaos. And according to 40-year market veteran Dr. David Eifrig, the biggest controlled demolition of the old monetary order in history could now be here, too. That means if you don't take action today, your wealth could decline by 40%... (Yes, even your cash savings.)
Cardlytics Stock Surges 5% After Hours As Citron Research Spotlights Wells Fargo Partnership
Cardlytics Inc. (NASDAQ: CDLX) saw its stock fall 9.85% during regular trading on Thursday. However, the stock rebounded in after-hours trading, climbing 5.04% to $2.50 following positive remarks from analysts.
Bitcoin Struggles Around $112,000, But Here's Why The Bull Run Is Not Over Yet
Bitcoin's (CRYPTO: BTC) is languishing around $112,000, but a prominent trader remains adamant about a strong end to the year.
Want To Know the No.1 Crypto and the No.1 Stock? - Ad
The #1 crypto is just $3. Crypto analysts say a cash injection could drive it as high as $100 in the next year. The #1 stock is equally exciting. It's less than $10 but made a HUGE deal recently to work with Nvidia.
Bitcoin, XRP, Dogecoin Rise On Interest Rate Cut Hopes; Ethereum Trades Flat: Analytics Firm Pumps The Brakes On Rally Hype
Leading cryptocurrencies gained on Tuesday, as investors increased their risk appetite in anticipation of a 25-basis-point rate cut.
Kevin O'Leary Once Admitted He Wasn't The Best Dad — But The Shark Gave Himself A '10 Out Of 10' Score In One Key Area
Kevin O'Leary admitted he wasn't always present as a father but said financial stability made him a "10 out of 10" provider, sharing how tough-love lessons with his son and sacrifices echoed by Barack Obama and Mark Cuban highlight the trade-offs between family and success.
Rare Disease Biotech Offers Access Ahead of Key Milestone - Ad
This late-stage biotech is gearing up for Phase 2 trials with an FDA-designated orphan drug. It's already drawing comparisons to recent billion-dollar exits. Backed by a proven biotech incubator, it's now offering early access to its raise.
AquaBounty Technologies Stock Explodes Over 98% After Hours: Here's Why
AquaBounty Technologies saw a massive 98.25% surge in after-hours trading to $2.26, following confirmation that it had met NASDAQ's minimum bid price requirement, resolving its earlier delisting risk.
Harvard Business School graduate arrested on charges he cheated fellow alums out of over $4 million
NEW YORK (AP) — A Harvard Business School graduate was arrested Thursday on fraud charges alleging he swindled fellow alumni of the prestigious school out of over $4 million in a Ponzi scheme, even assuring one investor they would soon “brag” about their “crazy gains” at the school's reunion.
Biotech With Multiple Orphan Drugs Is Quietly Opening Its Doors - Ad
A promising biotech developing treatments for rare childhood brain diseases is opening a new raise. Its lead drug has fast-track status, orphan designations, is nearing Phase 2 and backed by a Global Integrator.
Trump Warns Of Massive Debt, Peter Grandich Warns Of 'Most Dangerous Time in 40 Years,' Fed Trapped In Inflation And More: This Week In Economy
Peter Grandich warns that we're in the "most dangerous time in 40 years," as gold surges and the Fed faces challenges with inflation and unemployment.
Scam centers are spreading in East Timor, UN report says
BANGKOK (AP) — A suspected scam call operation and a suspicious network of companies was discovered with links to a new free trade zone in East Timor, the U.N. Office of Drugs and Crime said Thursday.
New Biotech Offering Targets $426B Rare Disease Market - Ad
The rare disease drug space is growing fast-and so is investor interest. With exclusivity, pricing power and major M&A moves, the rare disease space is getting interesting. This company has the science and the experience.
Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?'
Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.
Asian shares retreat after Intel helped drive Wall Street to more records
MANILA, Philippines (AP) — Asian shares mostly retreated Friday after a rally of technology stocks led by Nvidia and Intel
Elon's $25 Trillion Confession - Ad
Elon Musk: "Tesla will become a $25 trillion company." That would make Tesla 8x bigger than Apple today. How is that possible? He admits it's all thanks to this one AI breakthrough that will take AI out of our computer screens and manifest a 250x boom here in the real world.
Nvidia's Market Capitalization Surpasses Canada's GDP, As McKinsey Projects $1.7 Trillion AI Data Center Spend By 2030
Nvidia has become the world's most valuable company with a $4.32 trillion market cap — surpassing Canada's GDP.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.